Ireland-incorporated Endo International (Nasdaq: ENDP) has entered into a definitive agreement to sell Mexico City based Grupo Farmacéutico SOMAR to private equity firm Advent International for around $124 million subject to customary adjustments for cash, debt and working capital.
"Earlier this year, we disclosed our intention to divest non-core assets, including SOMAR, in order to re-direct our resources to our core areas of growth. Today, we are pleased to announce our agreement with Advent to divest SOMAR," said Paul Campanelli, president and chief executive of Endo.
"SOMAR is a leading player in the large, growing Mexican private generics market," said Juan Pablo Zucchini, a managing partner and head of the Latin American Healthcare practice at Advent International, adding: "This investment aligns well with our healthcare sector focus in the region."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze